Back to results
US 9,067,923 B2Granted
Substituted quinoxalines
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsToshimi Kanai, Kenji Uchida, Masakazu Honma, Yuichi Fukuda
Life of this patent
Estimating the term…
Abstract
A nitrogen-containing heterocyclic compound represented by formula (I-A): (wherein R1A represents lower alkyl which may be substituted with lower alkoxy, R3A represents lower alkyl substituted with fluorine atom(s), and R4A represents an optionally substituted aromatic heterocyclic group) or the like, or a pharmaceutically acceptable salt thereof; and the like, are provided.
Claims4
A nitrogen-containing heterocyclic compound selected from the group consisting of:
- N,N-dimethyl-2-(4-(2,2,2-trifluoro-1-(3-(propylsulfonamido)quinoxalin-2-yloxy)ethyl)piperidin-1-yl)isonicotinamide (compound 1),
- N,N-dimethyl-2-(4-(2,2,2-trifluoro-1-(3-(propylsulfonamido)quinoxalin-2-yloxy)ethyl)piperidin-1-yl)nicotinamide (compound 2),
- N,N-dimethyl-6-(4-(2,2,2-trifluoro-1-(3-(propylsulfonamido)quinoxalin-2-yloxy)ethyl)piperidin-1-yl)picolinamide (compound 3),
- N-(3-(1-(1-(6-cyanopyridin-3-yl)piperidin-4-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 4),
- 5-(4-(2,2,2-trifluoro-1-(3-(propylsulfonamido)quinoxalin-2-yloxy)ethyl)piperidin-1-yl)picolinamide (compound 5),
- N-(3-(1-(1-(4-cyanopyridin-2-yl)piperidin-4-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 6),
- N-(3-(1-(1-(5-cyanopyridin-3-yl)piperidin-4-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 7),
- N,N-dimethyl-6-(4-(2,2,2-trifluoro-1-(3-(propylsulfonamido)quinoxalin-2-yloxy)ethyl)piperidin-1-yl)nicotinamide (compound 8),
- N-(3-(1-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 9),
- 2-(4-(2,2,2-trifluoro-1-(3-(propylsulfonamido)quinoxalin-2-yloxy)ethyl)piperidin-1-yl)nicotinamide (compound 10),
- N-(3-(2,2,2-trifluoro-1-(1-(2-methyl-2H-tetrazol-5-yl)piperidin-4-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 11),
- N-(3-(2,2,2-trifluoro-1-(1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 12),
- N-(3-(2,2,2-trifluoro-1-(1-(pyrazin-2-yl)piperidin-4-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 13),
- N-(3-(2,2,2-trifluoro-1-(1-(pyrimidin-5-yl)piperidin-4-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 14),
- N-(3-(1-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 15),
- N-(3-(1-(1-(2-cyanopyridin-4-yl)piperidin-4-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 16),
- N-(3-(1-(1-(3-cyanopyridin-4-yl)piperidin-4-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 17),
- N-(3-(2,2,2-trifluoro-1-(1-(thiazol-2-yl)piperidin-4-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 18),
- 6-(4-(2,2,2-trifluoro-1-(3-(propylsulfonamido)quinoxalin-2-yloxy)ethyl)piperidin-1-yl)nicotinamide (compound 19),
- N-(3-(2,2,2-trifluoro-1-(1-(pyridin-2-yl)piperidin-4-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 20),
- N-(3-(2,2,2-trifluoro-1-(1-(pyridin-3-yl)piperidin-4-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 21), and
- N-(3-(2,2,2-trifluoro-1-(1-(pyridin-4-yl)piperidin-4-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 22);
- or
- a pharmaceutically acceptable salt thereof.
21 more elements
A nitrogen-containing heterocyclic compound selected from the group consisting of:
- N-(3-(1-(6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)-2-methoxyethanesulfonamide (compound 23),
- 2-methoxy-N-(3-(2,2,2-trifluoro-1-(6-(5-(methoxymethyl)-1,2,4-oxadiazol-3-yl)pyridin-3-yl)ethoxy)quinoxalin-2-yl)ethanesulfonamide (compound 24),
- N-(3-(1-(6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 25),
- N-(3-(2,2,2-trifluoro-1-(6-(5-(methoxymethyl)-1,2,4-oxadiazol-3-yl)pyridin-3-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 26), and
- 2-methoxy-N-(3-(2,2,2-trifluoro-1-(6-(5-methyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)ethoxy)quinoxalin-2-yl)ethanesulfonamide (compound 27);
- or
- a pharmaceutically acceptable salt thereof.
4 more elements
A nitrogen-containing heterocyclic compound selected from the group consisting of:
- (R)-N-(3-(2,2,2-trifluoro-1-(6-(5-methyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 28),
- (R)-2-methoxy-N-(3-(2,2,2-trifluoro-1-(6-(oxazol-5-yl)pyridin-3-yl)ethoxy)quinoxalin-2-yl)ethanesulfonamide (compound 30),
- (S)-N-(3-(1-(2-acetylthiazol-5-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 32),
- (R)-5-(4-(2,2,2-trifluoro-1-(3-(propylsulfonamido)quinoxalin-2-yloxy)ethyl)piperidin-1-yl)picolinamide (compound 34), and
- (R)-N-(3-(1-(6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)-2-methoxyethanesulfonamide (compound 37);
- or
- a pharmaceutically acceptable salt thereof.
4 more elements
A nitrogen-containing heterocyclic compound selected from the group consisting of:
- (S)-N-(3-(2,2,2-trifluoro-1-(6-(5-methyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)ethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 29),
- (S)-2-methoxy-N-(3-(2,2,2-trifluoro-1-(6-(oxazol-5-yl)pyridin-3-yl)ethoxy)quinoxalin-2-yl)ethanesulfonamide (compound 31),
- (R)-N-(3-(1-(2-acetylthiazol-5-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)propane-1-sulfonamide (compound 33),
- (S)-5-(4-(2,2,2-trifluoro-1-(3-(propylsulfonamido)quinoxalin-2-yloxy)ethyl)piperidin-1-yl)picolinamide (compound 35), and
- (S)-N-(3-(1-(6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)quinoxalin-2-yl)-2-methoxyethanesulfonamide (compound 36);
- or
- a pharmaceutically acceptable salt thereof.
4 more elements
Dependencies are inferred from the claim text.